Tradestie Institutional Equity Comparison Engine

XLV vs XBI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XLV Overall Edge

XLV Captures Institutional Edge (2โ€“0 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Health Care Select Sector SPDR Fund (XLV) driven by superior Momentum & Technical, Options & Structure. Fundamentally, XLV trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus XBI at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, XLV sits in UNCLASSIFIED (1st %ile IV; Dealer Gamma Walls on Pro) against XBI sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
XLV N/M vs XBI N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner XLV
1Y +16.4% vs +22.4% ยท 52W Pos 70% vs 47%
Options & Structure Winner XLV
UNCLASSIFIED (1st %ile IV) vs CONSOLIDATION (17th %ile IV)
XLV NYSE Arca
Health Care Select Sector SPDR Fund
Institutional Equity
$177.24
-0.12% 1D
Market Cap N/A
1M Return -2.24%
1Y Return +16.35%
Forward P/E N/M
Unified AI Score
48.1 / 100 HOLD
Tech 42.0 Fund 46.0 Flow 50.0 Mom 46.0
XBI NYSE Arca
SPDR S&P Biotech ETF
Institutional Equity
$140.18
-2.73% 1D
Market Cap N/A
1M Return -7.56%
1Y Return +22.43%
Forward P/E N/M
Unified AI Score
52.9 / 100 HOLD
Tech 23.0 Fund 51.0 Flow 57.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XLV +16.35% XBI +22.43% Spread: +6.08 pp (XBI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XLV TTM Op. Margin: N/A XBI TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLV vs XBI. Trailing 12-month operating profitability (XLV N/A vs XBI N/A) and valuation multiples (XLV N/M vs XBI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XLV (2) vs XBI (1)
Institutional Metric XLV XBI Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 70% ($142โ€“$192) 47% ($113โ€“$170) Stronger Trend XLV
Beta / 30D Volatility Risk Regime 0.26ฮฒ ยท 22% Vol 1.17ฮฒ ยท 38% Vol Lower Realized Risk XLV
Unified Institutional Score Composite Signal 48.1 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite XBI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XLV vs XBI Buy Guide
XLV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live XLV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XBI CONSOLIDATION
66d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live XBI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XLV nor XBI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.